RTP Mobile Logo
Meet the Investigators: New Agents and Strategies in the Management of Ovarian Cancer
Released August 2017

Proceedings from a CME symposium held at the 2017 ASCO Annual Meeting. Featuring perspectives from Drs Michael Birrer, Joyce F Liu and Mansoor Raza Mirza. (Video Program)

CE Disclosures and Faculty Information

    This activity is intended for medical oncologists, gynecologic oncologists and other healthcare providers involved in the treatment of ovarian cancer (OC).

    The American Cancer Society estimates that 22,440 new cases of OC will be diagnosed in the United States in 2017 and 14,080 individuals will die of the disease. For this reason, significant financial and intellectual resources have been invested over the past few decades in attempts to better understand the natural history of the disease, identify genetic and other factors responsible for its proliferation and develop novel therapies with the potential to significantly improve outcomes for patients. The successes yielded by this rational approach to the design and evaluation of new therapies have culminated in a number of FDA approvals and clinical trials attempting to document the efficacy of new agents across multiple OC populations. These same successes have given rise to clinical and research questions for practicing clinicians regarding the therapeutic management of this disease.

    These video proceedings from a CME symposium held during the 2017 ASCO Annual Meeting feature discussions with leading OC researchers regarding actual patient cases and related clinical research findings. By providing information on the latest research developments and their potential application to routine practice, this activity is designed not only to improve clinicians’ knowledge of recent data related to the rapidly evolving ovarian oncology treatment landscape but also to provide them with practical perspectives to help them become better and more effective caregivers.


    • Review clinical investigator perspectives on the selection of validated genetic testing platforms for patients with OC and on the implications of these findings for long-term treatment planning.
    • Appreciate the recent FDA approval of niraparib as maintenance therapy for patients with recurrent, platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer, and safely integrate this agent into routine clinical practice.
    • Develop an understanding of the efficacy data and toxicity profiles of approved and investigational PARP inhibitors for patients with advanced OC to effectively formulate protocol and nonresearch treatment recommendations for these individuals.
    • Evaluate available Phase III data investigating the efficacy of olaparib as maintenance therapy for patients with BRCA mutation-positive, recurrent, platinum-sensitive OC who are responding to platinum-based chemotherapy.
    • Recognize the mechanisms of action, emerging efficacy data and toxicity profiles of novel targeted agents and immunotherapeutic approaches under investigation in OC, and prioritize clinical trial opportunities for appropriate patients.

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue

    CME credit is no longer available for this issue

    This CME activity consists of a video component.
    CME credit is no longer available for this issue

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Michael Birrer, MD, PhD
    Director, UAB Comprehensive Cancer Center
    University of Alabama at Birmingham
    Birmingham, Alabama

    Advisory Committee: Roche Laboratories Inc.

    Joyce F Liu, MD, MPH
    Director of Clinical Research, Gynecologic Oncology 
    Assistant Professor of Medicine
    Harvard Medical School
    Dana-Farber Cancer Institute
    Boston, Massachusetts

    Advisory Committee: AstraZeneca Pharmaceuticals LP, Tesaro Inc; Consulting Agreement: AstraZeneca Pharmaceuticals LP. 

    Mansoor Raza Mirza, MD
    Medical Director, Nordic Society of Gynecologic Oncology
    Chief Oncologist, Department of Oncology
    Rigshospitalet, Copenhagen University Hospital
    Copenhagen, Denmark 

    Board of Directors: Karyopharm Therapeutics, Metamark Genetics Inc, Sera Prognostics; Consulting Agreements: Advaxis Inc, AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Cerulean Pharma Inc, Clovis Oncology, Genmab, Karyopharm Therapeutics, Novocure, Pfizer Inc, Roche Laboratories Inc, Tesaro Inc; Paid Research: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Clovis Oncology, Pfizer Inc, Roche Laboratories Inc, Tesaro Inc.

    MODERATOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Baxalta Inc, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, CTI BioPharma Corp, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Medivation Inc, a Pfizer Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, NanoString Technologies, Natera Inc, Novartis, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro Inc, Teva Oncology and Tokai Pharmaceuticals Inc.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from AbbVie Inc, AstraZeneca Pharmaceuticals LP, ImmunoGen Inc and Tesaro Inc. 

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
    Adobe Flash Player 10.2 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: August 2017
    Expiration date: August 2018

Acknowledge and close

Watch videos
(WIFI is recommended for best performance):